You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Chapter title |
Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease
|
|---|---|
| Chapter number | 3 |
| Book title |
Gene and Cell Therapies for Beta-Globinopathies
|
| Published in |
Advances in experimental medicine and biology, November 2017
|
| DOI | 10.1007/978-1-4939-7299-9_3 |
| Pubmed ID | |
| Book ISBNs |
978-1-4939-7297-5, 978-1-4939-7299-9
|
| Authors |
Chonat, Satheesh, Quinn, Charles T., Satheesh Chonat, Charles T. Quinn |
| Abstract |
Thalassemia and sickle cell disease (SCD) are disorders of hemoglobin that affect millions of people worldwide. The carrier states for these diseases arose as common, balanced polymorphisms during human history because they afforded protection against severe forms of malaria. These complex, multisystem diseases are reviewed here with a focus on current standards of clinical management and recent research findings. The importance of a comprehensive, multidisciplinary and lifelong system of care is also emphasized. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 127 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 127 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 27 | 21% |
| Student > Ph. D. Student | 14 | 11% |
| Student > Master | 10 | 8% |
| Other | 8 | 6% |
| Lecturer | 5 | 4% |
| Other | 17 | 13% |
| Unknown | 46 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 26% |
| Biochemistry, Genetics and Molecular Biology | 13 | 10% |
| Nursing and Health Professions | 8 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 6% |
| Immunology and Microbiology | 3 | 2% |
| Other | 10 | 8% |
| Unknown | 53 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 February 2024.
All research outputs
#3,705,859
of 25,378,284 outputs
Outputs from Advances in experimental medicine and biology
#613
of 5,246 outputs
Outputs of similar age
#65,982
of 338,941 outputs
Outputs of similar age from Advances in experimental medicine and biology
#8
of 29 outputs
Altmetric has tracked 25,378,284 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,246 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,941 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.